Australasian Journal of Dermatology · 2024 · 10 citations · 3 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyImmunotherapyPain ManagementAnti-inflammatory PharmacologyImmunotherapy Safety
In this original research, we present the results in terms of effectiveness and safety of bimekizumab for hidradenitis suppurativa in real clinical practice. Results indicated significant improvement in all activity scores and patient-reported outcomes at week 16, including a notable decrease in mean IHS4 from 27.1 to 15.6 (p < 0.001), HS-PGA from 5.1 to 3.2 (p < 0.001), VAS pain from 8.3 to 4.7 (p < 0.001) and DLQI from 21.6 to 12.6 (p < 0.001). Bimekizumab, administered every 2 or 4 weeks, was well-tolerated with no discontinuations and no new safety concerns identified. These findings corroborate the drug's effectiveness and favourable safety profile observed in phase 3 clinical trials, supporting its use in real-world clinical practice for treating HS.
3
Bimekizumab versus Secukinumab in Plaque Psoriasis
Kristian Reich, Richard B. Warren, Mark Lebwohl et al. · New England Journal of Medicine · 2021 · 400 citations
Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa
Sophie Glatt, Gregor B. E. Jemec, Seth Forman et al. · JAMA Dermatology · 2021 · 167 citations · Full text